Allergan PLC. (AGN) Holdings Boosted by Lincoln National Corp

Lincoln National Corp grew its position in shares of Allergan PLC. (NYSE:AGN) by 3.6% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,031 shares of the company’s stock after buying an additional 36 shares during the quarter. Lincoln National Corp’s holdings in Allergan PLC. were worth $251,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently bought and sold shares of the company. Jacobi Capital Management LLC lifted its position in shares of Allergan PLC. by 4.9% during the 1st quarter. Jacobi Capital Management LLC now owns 472 shares of the company’s stock worth $112,000 after buying an additional 22 shares in the last quarter. JNBA Financial Advisors lifted its position in shares of Allergan PLC. by 2.5% during the 1st quarter. JNBA Financial Advisors now owns 487 shares of the company’s stock worth $116,000 after buying an additional 12 shares in the last quarter. Webster Bank N. A. lifted its position in shares of Allergan PLC. by 31.0% during the 1st quarter. Webster Bank N. A. now owns 520 shares of the company’s stock worth $124,000 after buying an additional 123 shares in the last quarter. Pacific Center for Financial Services lifted its position in shares of Allergan PLC. by 805.1% during the 1st quarter. Pacific Center for Financial Services now owns 534 shares of the company’s stock worth $128,000 after buying an additional 475 shares in the last quarter. Finally, Ropes Wealth Advisors LLC lifted its position in shares of Allergan PLC. by 31.0% during the 1st quarter. Ropes Wealth Advisors LLC now owns 575 shares of the company’s stock worth $137,000 after buying an additional 136 shares in the last quarter. 82.06% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: “Allergan PLC. (AGN) Holdings Boosted by Lincoln National Corp” was originally posted by Markets Daily and is the property of of Markets Daily. If you are reading this story on another domain, it was illegally copied and republished in violation of international copyright and trademark laws. The legal version of this story can be viewed at https://www.themarketsdaily.com/2017/09/13/allergan-plc-agn-holdings-boosted-by-lincoln-national-corp.html.

A number of equities research analysts recently commented on the stock. Cowen and Company set a $400.00 price target on shares of Allergan PLC. and gave the stock a “buy” rating in a report on Thursday, June 8th. Sanford C. Bernstein reaffirmed an “outperform” rating on shares of Allergan PLC. in a report on Thursday, May 25th. Mizuho lowered their price target on shares of Allergan PLC. from $275.00 to $267.00 and set a “buy” rating on the stock in a report on Friday, June 9th. Royal Bank Of Canada reaffirmed a “buy” rating and issued a $285.00 price target on shares of Allergan PLC. in a report on Wednesday, September 6th. Finally, Cantor Fitzgerald assumed coverage on shares of Allergan PLC. in a report on Friday, June 16th. They issued a “neutral” rating and a $231.00 price target on the stock. One analyst has rated the stock with a sell rating, seven have given a hold rating and fifteen have given a buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $274.69.

Allergan PLC. (NYSE AGN) opened at 231.21 on Wednesday. The stock has a market capitalization of $77.29 billion, a price-to-earnings ratio of 7.04 and a beta of 1.18. The stock’s 50 day moving average is $235.09 and its 200-day moving average is $237.04. Allergan PLC. has a 52-week low of $184.50 and a 52-week high of $256.80.

Allergan PLC. (NYSE:AGN) last released its quarterly earnings results on Thursday, August 3rd. The company reported $4.02 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $3.95 by $0.07. Allergan PLC. had a net margin of 79.17% and a return on equity of 7.37%. The business had revenue of $4.01 billion for the quarter, compared to the consensus estimate of $3.95 billion. During the same period last year, the firm earned $3.35 earnings per share. The company’s quarterly revenue was up 8.8% on a year-over-year basis. Equities research analysts anticipate that Allergan PLC. will post $16.25 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, September 15th. Shareholders of record on Friday, August 18th will be given a $0.70 dividend. The ex-dividend date of this dividend is Wednesday, August 16th. This represents a $2.80 annualized dividend and a yield of 1.21%. Allergan PLC.’s payout ratio is presently 9.95%.

Allergan PLC. Profile

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan PLC. (NYSE:AGN).

Institutional Ownership by Quarter for Allergan PLC. (NYSE:AGN)

Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply